Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Veny, Marisol, Garrido-Trigo, Alba, Corraliza, Ana M, Masamunt, Maria C, Bassolas-Molina, Helena, Esteller, Miriam, Arroyes, Montserrat, Tristán, Eva, Fernández-Clotet, Agnès, Ordás, Ingrid, Ricart, Elena, Esteve, Maria, Panés, Julian, Salas, Azucena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://www.ncbi.nlm.nih.gov/pubmed/32926095
http://dx.doi.org/10.1093/ecco-jcc/jjaa178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://www.ncbi.nlm.nih.gov/pubmed/32926095
http://dx.doi.org/10.1093/ecco-jcc/jjaa178

Ejemplares similares